| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.8M | — | +13.9% |
| SG&A Expense | $1.5M | — | +20.9% |
| Operating Income | -$3.3M | — | -17.0% |
| Pre-tax Income | -$3.4M | — | -19.1% |
| Net Income | -$3.4M | — | -19.1% |
| EPS (Basic) | -$1.29 | — | -330.0% |
| EPS (Diluted) | -$1.29 | — | -330.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.7M | -69.5% | -41.6% |
| Current Assets | $1.9M | -65.8% | -48.4% |
| Total Assets | $4.5M | -42.1% | -6.0% |
| Current Liabilities | $2.0M | -11.5% | +54.3% |
| Total Liabilities | $2.0M | -11.5% | +54.3% |
| Stockholders' Equity | $2.5M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.6M | — | -31.5% |
| Investing Cash Flow | -$500K | — | — |
| Financing Cash Flow | $245K | — | -94.5% |
| -28.0% |